Oh! I co-authored a #hemophilia article in #Nature Reviews Drug Discovery 🤗 it published May 21. Click on the link to read my and @ggreen_DRG’s take on the hemophilia drug market: https://t.co/kKBuLGNzeC #DRG
"HCV is beautiful in its simplicity; NASH is fascinating in its complexity". Very nice talk from @Novartis at the afternoon session of the #NASHCONGRESS on the potential for combination therapies in NASH. @DRGinsights#NASH
Another fascinating morning session at the #NASHCONGRESS, with 3 talks on the future of non-invasive biomarkers in NASH. Some really nice visual examples from @LiverMultiScan. #NASH
"With four emerging therapies in Phase III trials for NASH, we are at an exciting point in the disease’s history; the first approved therapies are within our grasp." @AFrost_DRG blog on NASH congress $GILD $GNFT $ICPT https://t.co/dHVYQEp9WS
Unlike $NVO ‘s excluded GLP-1 Victoza, the new once-weekly Ozempic will be included on Express Scripts tier 3. Crucial to compete with the preferred status GLP-1s from $LLY $AZN (Trulicity, Byetta, Bydureon). Expect Ozempic to take a big bite out of Trulicity’s growth. #diabetes